View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsIndivior 将来の成長Future 基準チェック /46現在、 Indiviorの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報40.4%収益成長率42.37%EPS成長率Pharmaceuticals 収益成長21.7%収益成長率11.9%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日06 Jun 2023今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 23Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like FentanylIndivior PLC announced that the U.S. Food and Drug Administration (FDA) approved OPVEE® (nalmefene) nasal spray for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE contains nalmefene, an opioid receptor antagonist that provides fast onset and long duration reversal of opioid-induced respiratory depression, which is the primary cause of opioid overdose injury and death. OPVEE was designed to address the challenges of today's opioid crisis. OPVEE was approved via the 505(b)(2) pathway. In a first of its kind pharmacodynamic study (NCT04828005) in 61 opioid-experienced, non-dependent subjects, the effect of 2.7 mg OPVEE was assessed on remifentanil-induced respiratory depression. Following OPVEE administration, the time to onset of reversal of respiratory depression was observed between 2.5 to 5 minutes and full recovery of respiratory drive was manifested as early as 5 minutes after OPVEE administration. The duration of action of nalmefene is as long as most opioids, including fentanyl. These attributes are well-suited to address the challenges of today's opioid overdose crisis. The speed of action, long duration, and high potency of fentanyl and other synthetic opioids are driving unprecedented overdose deaths across a broader range of ages, and they are now a leading cause of death for people ages 18 to 45.5 For each opioid-induced fatality, it has been estimated that there are an additional 6.4-8.4 non-fatal overdoses that can lead to long-term physical and mental disability. A federally funded contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, for up to $10.8 million, combined with a $7.4 million U01 "grand opportunities in medications development" grant received from the National Institute on Drug Abuse (NIDA), supported the development of OPVEE. The contract (number HHSO100201800029C) with BARDA was intended to develop OPVEE for reversal of opioid overdoses in the community and as a medical countermeasure and reversal agent in the event of a chemical attack using synthetic opioids. OPVEE is expected to be in the market in Fourth Quarter of 2023. Indivior added OPVEE to its portfolio with the acquisition of Opiant Pharmaceuticals Inc., which closed March 2, 2023. As previously indicated, Indivior believes the clinical profile of OPVEE supports the potential for this treatment to deliver annual net revenue of $150 million to $250 million, with expected earnings accretion from the Opiant acquisition after the second full year of launch of OPVEE.お知らせ • Feb 17Indivior PLC Announces Board and Committee ChangesIndivior PLC announced that Juliet Thompson has been appointed as Senior Independent Director with effect from October 1, 2023. Juliet has been a Non-Executive Director since March 2021 and is the Chair of the Audit Committee and a member of the Nomination & Governance Committee. The Company further announces that Jo Le Couilliard has been appointed as Chair of the Remuneration Committee also with effect from October 1, 2023. Jo has been a Non-Executive Director since March 2021 and is a member of the Audit and Remuneration Committees. This announcement follows the Company's previous announcement on October 13, 2022 that Daniel J. Phelan, current Senior Independent Director and Chair of the Remuneration Committee, will stand down from the Board on September 30, 2022 having served as a Director for nine years.お知らせ • Jan 12Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023Indivior PLC announced that they will report Q4, 2022 results at 2:00 AM, US Eastern Standard Time on Feb 16, 2023お知らせ • Nov 28Reckitt Benckiser Group Submits Claim against Indivior PLCIndivior PLC announced it has been made aware that a claim was submitted to the Commercial Court in London by Reckitt Benckiser Group plc ('RB') against the company on November 13, 2020 pursuant to an indemnity contained in the Demerger Agreement entered into between RB and the Company on November 17, 2014. The amount claimed under the submission is £1,073,622.580.51. The claim has not been served on the company and the company does not have any further details at this time. The company will assess with its advisors the background and merits to the case and will provide an update in due course.お知らせ • Nov 21+ 1 more updateIndivior PLC Announces the Appointment of Ryan Preblick as Executive DirectorThe Board of Directors of Indivior PLC announced the appointment of Ryan Preblick as Executive Director with immediate effect. Ryan has been serving as Interim Chief Financial Officer since June 2020 and has been in financial leadership roles since joining Indivior in 2012. Prior to his appointment as Interim Chief Financial Officer in June 2020, Ryan was Senior Vice President, Global Financial Planning and Analysis Commercial Operations. This role included overseeing all key financial management, analysis and reporting elements of the Group's global business. Prior to that, Ryan was Vice President, US Finance with responsibility overseeing all financial areas of the US business, the Group's large business, including management, planning, analysis and reporting, government pricing and managed care contracting operations. Ryan started his career in corporate finance at Honeywell International and then spent twelve years at Altria Company (including Philip Morris USA) in finance leadership roles of increasing responsibility working with Treasury, Financial Planning & Analysis, Market Analytics, Supply Chain and Brand Decision Support. Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond.お知らせ • Nov 19Indivior PLC Announces Executive ChangesIndivior PLC announced the appointment of Graham Hetherington as Chair of the Board with immediate effect. Graham's appointment was approved by the Board and follows a succession process undertaken by the Nomination & Governance Committee and led by Lorna Parker, Chair of the Nomination & Governance Committee. Graham will step down as Chair of the Audit Committee. Daniel Tassé will remain the Senior Independent Director and will be appointed Chair of the Audit Committee, effective immediately. Daniel has been a member of the Audit Committee since the Company listed in 2014 and served as Chair of the Audit Committee between July 2019 and March 2020. Graham will be appointed as a member of the Nomination & Governance Committee and will remain a member of the Audit and Remuneration Committees. The Board also intends to undertake a search to identify an additional independent Non-Executive Director with recent and relevant financial experience.お知らせ • Sep 30Indivior PLC to Report Q3, 2020 Results on Oct 29, 2020Indivior PLC announced that they will report Q3, 2020 results on Oct 29, 2020お知らせ • Sep 21Indivior PLC(LSE:INDV) dropped from FTSE All-Small Index (GBP)Indivior PLC(LSE:INDV) dropped from FTSE All-Small Index (GBP)お知らせ • Jul 18Indivior PLC to Report Q2, 2020 Results on Jul 30, 2020Indivior PLC announced that they will report Q2, 2020 results at 2:00 AM, US Eastern Standard Time on Jul 30, 2020お知らせ • Jun 29Indivior PLC Announces CEO ChangesIndivior PLC announced that effective June 29, 2020, the Board of Directors has appointed Mark Crossley as Chief Executive Officer. Shaun Thaxter, in mutual agreement with the Board, is stepping down as Chief Executive Officer and Executive Director. Mr. Crossley has been Chief Financial and Operations Officer (CFOO) and Executive Director of Indivior since February 2017. He was previously Chief Strategy Officer from 2014-2017 and served as Finance Director where he led the demerger of Indivior from its former parent. Prior to joining Indivior in 2012, Mark spent thirteen years at Procter & Gamble in various finance leadership positions and eight years as an officer in the United States Coast Guard.業績と収益の成長予測DB:2IVA - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20251,287307279285212/31/20241,134250157213412/31/20231,018169-381443/31/2023947-502335N/A12/31/2022901-53-9-4N/A9/30/2022883166176181N/A6/30/2022838152160145N/A3/31/2022818166175189N/A12/31/2021791205339353N/A9/30/2021753156101115N/A6/30/202172513981115N/A3/31/2021674953942N/A12/31/2020647-148-197-193N/A9/30/2020595-190-84-82N/A6/30/2020634-152-70-69N/A3/31/2020700-95-131-130N/A12/31/2019785134148151N/A9/30/2019889213217200N/A6/30/2019935254281275N/A3/31/2019988248401413N/A12/31/20181,005275299303N/A9/30/20181,033106247276N/A6/30/20181,06467171210N/A3/31/20181,08371231260N/A12/31/20171,09358252295N/A9/30/20171,087281310360N/A6/30/20171,08081371409N/A3/31/20171,06565331370N/A12/31/20161,05835N/A407N/A9/30/20161,047-6N/A326N/A6/30/20161,028191N/A283N/A3/31/20161,021201N/A252N/A12/31/20151,014228N/A320N/A9/30/20151,037268N/A300N/A6/30/20151,058314N/A369N/A3/31/20151,085361N/A530N/A12/31/20141,115403N/A440N/A9/30/20141,147443N/A572N/A12/31/20131,216489N/A791N/A12/31/20121,339607N/A866N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 2IVAは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 0.2% ) よりも高い成長率であると考えられます。収益対市場: 2IVA今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: 2IVA今後 3 年以内に収益を上げることが予想されます。収益対市場: 2IVAの収益 ( 11.9% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: 2IVAの収益 ( 11.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 2IVAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/06/13 21:21終値2023/05/29 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Indivior Pharmaceuticals, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Graham Glyn ParryBofA Global ResearchChase KnickerbockerCraig-Hallum Capital Group LLCBrandon FolkesH.C. Wainwright & Co.6 その他のアナリストを表示
お知らせ • May 23Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like FentanylIndivior PLC announced that the U.S. Food and Drug Administration (FDA) approved OPVEE® (nalmefene) nasal spray for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE contains nalmefene, an opioid receptor antagonist that provides fast onset and long duration reversal of opioid-induced respiratory depression, which is the primary cause of opioid overdose injury and death. OPVEE was designed to address the challenges of today's opioid crisis. OPVEE was approved via the 505(b)(2) pathway. In a first of its kind pharmacodynamic study (NCT04828005) in 61 opioid-experienced, non-dependent subjects, the effect of 2.7 mg OPVEE was assessed on remifentanil-induced respiratory depression. Following OPVEE administration, the time to onset of reversal of respiratory depression was observed between 2.5 to 5 minutes and full recovery of respiratory drive was manifested as early as 5 minutes after OPVEE administration. The duration of action of nalmefene is as long as most opioids, including fentanyl. These attributes are well-suited to address the challenges of today's opioid overdose crisis. The speed of action, long duration, and high potency of fentanyl and other synthetic opioids are driving unprecedented overdose deaths across a broader range of ages, and they are now a leading cause of death for people ages 18 to 45.5 For each opioid-induced fatality, it has been estimated that there are an additional 6.4-8.4 non-fatal overdoses that can lead to long-term physical and mental disability. A federally funded contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, for up to $10.8 million, combined with a $7.4 million U01 "grand opportunities in medications development" grant received from the National Institute on Drug Abuse (NIDA), supported the development of OPVEE. The contract (number HHSO100201800029C) with BARDA was intended to develop OPVEE for reversal of opioid overdoses in the community and as a medical countermeasure and reversal agent in the event of a chemical attack using synthetic opioids. OPVEE is expected to be in the market in Fourth Quarter of 2023. Indivior added OPVEE to its portfolio with the acquisition of Opiant Pharmaceuticals Inc., which closed March 2, 2023. As previously indicated, Indivior believes the clinical profile of OPVEE supports the potential for this treatment to deliver annual net revenue of $150 million to $250 million, with expected earnings accretion from the Opiant acquisition after the second full year of launch of OPVEE.
お知らせ • Feb 17Indivior PLC Announces Board and Committee ChangesIndivior PLC announced that Juliet Thompson has been appointed as Senior Independent Director with effect from October 1, 2023. Juliet has been a Non-Executive Director since March 2021 and is the Chair of the Audit Committee and a member of the Nomination & Governance Committee. The Company further announces that Jo Le Couilliard has been appointed as Chair of the Remuneration Committee also with effect from October 1, 2023. Jo has been a Non-Executive Director since March 2021 and is a member of the Audit and Remuneration Committees. This announcement follows the Company's previous announcement on October 13, 2022 that Daniel J. Phelan, current Senior Independent Director and Chair of the Remuneration Committee, will stand down from the Board on September 30, 2022 having served as a Director for nine years.
お知らせ • Jan 12Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023Indivior PLC announced that they will report Q4, 2022 results at 2:00 AM, US Eastern Standard Time on Feb 16, 2023
お知らせ • Nov 28Reckitt Benckiser Group Submits Claim against Indivior PLCIndivior PLC announced it has been made aware that a claim was submitted to the Commercial Court in London by Reckitt Benckiser Group plc ('RB') against the company on November 13, 2020 pursuant to an indemnity contained in the Demerger Agreement entered into between RB and the Company on November 17, 2014. The amount claimed under the submission is £1,073,622.580.51. The claim has not been served on the company and the company does not have any further details at this time. The company will assess with its advisors the background and merits to the case and will provide an update in due course.
お知らせ • Nov 21+ 1 more updateIndivior PLC Announces the Appointment of Ryan Preblick as Executive DirectorThe Board of Directors of Indivior PLC announced the appointment of Ryan Preblick as Executive Director with immediate effect. Ryan has been serving as Interim Chief Financial Officer since June 2020 and has been in financial leadership roles since joining Indivior in 2012. Prior to his appointment as Interim Chief Financial Officer in June 2020, Ryan was Senior Vice President, Global Financial Planning and Analysis Commercial Operations. This role included overseeing all key financial management, analysis and reporting elements of the Group's global business. Prior to that, Ryan was Vice President, US Finance with responsibility overseeing all financial areas of the US business, the Group's large business, including management, planning, analysis and reporting, government pricing and managed care contracting operations. Ryan started his career in corporate finance at Honeywell International and then spent twelve years at Altria Company (including Philip Morris USA) in finance leadership roles of increasing responsibility working with Treasury, Financial Planning & Analysis, Market Analytics, Supply Chain and Brand Decision Support. Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond.
お知らせ • Nov 19Indivior PLC Announces Executive ChangesIndivior PLC announced the appointment of Graham Hetherington as Chair of the Board with immediate effect. Graham's appointment was approved by the Board and follows a succession process undertaken by the Nomination & Governance Committee and led by Lorna Parker, Chair of the Nomination & Governance Committee. Graham will step down as Chair of the Audit Committee. Daniel Tassé will remain the Senior Independent Director and will be appointed Chair of the Audit Committee, effective immediately. Daniel has been a member of the Audit Committee since the Company listed in 2014 and served as Chair of the Audit Committee between July 2019 and March 2020. Graham will be appointed as a member of the Nomination & Governance Committee and will remain a member of the Audit and Remuneration Committees. The Board also intends to undertake a search to identify an additional independent Non-Executive Director with recent and relevant financial experience.
お知らせ • Sep 30Indivior PLC to Report Q3, 2020 Results on Oct 29, 2020Indivior PLC announced that they will report Q3, 2020 results on Oct 29, 2020
お知らせ • Sep 21Indivior PLC(LSE:INDV) dropped from FTSE All-Small Index (GBP)Indivior PLC(LSE:INDV) dropped from FTSE All-Small Index (GBP)
お知らせ • Jul 18Indivior PLC to Report Q2, 2020 Results on Jul 30, 2020Indivior PLC announced that they will report Q2, 2020 results at 2:00 AM, US Eastern Standard Time on Jul 30, 2020
お知らせ • Jun 29Indivior PLC Announces CEO ChangesIndivior PLC announced that effective June 29, 2020, the Board of Directors has appointed Mark Crossley as Chief Executive Officer. Shaun Thaxter, in mutual agreement with the Board, is stepping down as Chief Executive Officer and Executive Director. Mr. Crossley has been Chief Financial and Operations Officer (CFOO) and Executive Director of Indivior since February 2017. He was previously Chief Strategy Officer from 2014-2017 and served as Finance Director where he led the demerger of Indivior from its former parent. Prior to joining Indivior in 2012, Mark spent thirteen years at Procter & Gamble in various finance leadership positions and eight years as an officer in the United States Coast Guard.